Audentes Therapeutics, Inc. (NASDAQ:BOLD) – Equities researchers at William Blair issued their Q3 2017 earnings estimates for shares of Audentes Therapeutics in a research report issued to clients and investors on Tuesday. William Blair analyst R. Prasad forecasts that the biotechnology company will post earnings per share of ($0.91) for the quarter. William Blair has a “Outperform” rating and a $35.00 price target on the stock. William Blair also issued estimates for Audentes Therapeutics’ Q4 2017 earnings at ($0.80) EPS, FY2017 earnings at ($3.40) EPS, FY2018 earnings at ($3.44) EPS, FY2019 earnings at ($3.69) EPS, FY2020 earnings at ($3.58) EPS and FY2021 earnings at ($3.61) EPS.
Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.10). COPYRIGHT VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/28/research-analysts-set-expectations-for-audentes-therapeutics-inc-s-q3-2017-earnings-bold.html.
A number of other brokerages have also issued reports on BOLD. ValuEngine lowered Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, October 13th. Raymond James Financial, Inc. assumed coverage on Audentes Therapeutics in a research note on Thursday, October 12th. They set a “market perform” rating for the company. Bank of America Corporation reaffirmed a “buy” rating and set a $33.00 target price (up from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. Zacks Investment Research lowered Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, Evercore ISI assumed coverage on Audentes Therapeutics in a research report on Wednesday, August 16th. They set an “outperform” rating and a $23.00 target price for the company. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Audentes Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $25.71.
Audentes Therapeutics (NASDAQ:BOLD) opened at 25.41 on Thursday. The company’s market cap is $705.99 million. The company’s 50 day moving average price is $26.69 and its 200-day moving average price is $26.69. Audentes Therapeutics has a one year low of $13.13 and a one year high of $33.43.
In other Audentes Therapeutics news, SVP Mary Newman sold 10,000 shares of Audentes Therapeutics stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. Following the completion of the sale, the senior vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $200,000. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Suyash Prasad sold 8,000 shares of Audentes Therapeutics stock in a transaction on Friday, September 1st. The shares were sold at an average price of $21.44, for a total value of $171,520.00. Following the sale, the vice president now directly owns 8,000 shares of the company’s stock, valued at $171,520. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 766,500 shares of company stock valued at $21,443,730. 47.30% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in the company. Ardsley Advisory Partners increased its holdings in shares of Audentes Therapeutics by 59.7% in the 2nd quarter. Ardsley Advisory Partners now owns 20,072 shares of the biotechnology company’s stock valued at $384,000 after acquiring an additional 7,500 shares during the period. California State Teachers Retirement System increased its holdings in shares of Audentes Therapeutics by 128.8% in the 2nd quarter. California State Teachers Retirement System now owns 27,000 shares of the biotechnology company’s stock valued at $517,000 after acquiring an additional 15,200 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Audentes Therapeutics by 1,086.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,580 shares of the biotechnology company’s stock valued at $260,000 after acquiring an additional 12,435 shares during the period. Redmile Group LLC increased its holdings in shares of Audentes Therapeutics by 77.8% in the 2nd quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after acquiring an additional 638,780 shares during the period. Finally, State Street Corp increased its holdings in shares of Audentes Therapeutics by 231.6% in the 2nd quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock valued at $4,234,000 after acquiring an additional 154,544 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.